NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

亨丁頓舞蹈症:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Huntington's Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024223
出版日期 內容資訊 英文 245 Pages
商品交期: 3-5個工作天內
價格
亨丁頓舞蹈症:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Huntington's Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 245 Pages
簡介

本報告提供亨丁頓舞蹈症市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·適應症·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 亨丁頓舞蹈症的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 亨丁頓舞蹈症的交易趨勢

第7章 亨丁頓舞蹈症的開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH645

GervanoRA's pipeline analysis and opportunity assessment report "Huntington's Disease - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Huntington's Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Huntington's Disease drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Huntington's Disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Huntington's Disease drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Huntington's Disease historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Huntington's Disease Market (2020) and the Forecasted Huntington's Disease Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Huntington's Disease Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Huntington's Disease Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Huntington's Disease Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: HUNTINGTON'S DISEASE CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF HUNTINGTON'S DISEASE COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF HUNTINGTON'S DISEASE PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: HUNTINGTON'S DISEASE REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: NUMBER OF CAG REPEATS AND OUTCOMES IN HUNTINGTON'S DISEASE
  • TABLE 03: HUNTINGTON'S DISEASE PREVALENCE, EUROPEAN COUNTRIES
  • TABLE 04: HUNTINGTON'S DISEASE PREVALENCE, AMERICA
  • TABLE 05: HUNTINGTON'S DISEASE PREVALENCE, ASIAN COUNTRIES
  • TABLE 06: COLLABORATION DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 07: FINANCING DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 08: LICENSING DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 09: MERGER AND ACQUISITION DEALS IN HUNTINGTON DISEASE THERAPEUTIC AREA
  • TABLE 10: HUNTINGTON'S DISEASE PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 11: PHASE 3 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 12: PHASE 2 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 13: PHASE 1/2 PIPELINE MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 14: PHASE 1 MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 15: PRECLINICAL MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 16: EARLY RESEARCH AND DEVELOPMENT MOLECULES FOR TREATING HUNTINGTON'S DISEASE
  • TABLE 17: CLINICAL STAGE DRUG CANDIDATES ALONG WITH SPECIAL REGULATORY ALLOWANCES
  • TABLE 18: PRECLINICAL STAGE DRUG CANDIDATES ALONG WITH SPECIAL REGULATORY ALLOWANCES
  • TABLE 19: HUNTINGTON'S DISEASE PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 20: HUNTINGTON'S DISEASE PIPELINE ANALYTICS BY ORAL AS ROA
  • TABLE 21: LIST OF PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 22: LIST OF PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 23: HUNTINGTON'S DISEASE PIPELINE DRUGS, TREATMENT TYPE
  • TABLE 24: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 25: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF HUNTINGTON'S DISEASE PIPELINE CANDIDATES

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE HUNTINGTON'S DISEASE COMPETITIVE SPACE
  • FIGURE 02: ORIGINAL AND MUTATED DNA SEQUENCE OF HTT GENE
  • FIGURE 03: HD EXPECTED POPULATION FOR YEAR 2019 & 2025 IN THE US
  • FIGURE 04: HUNTINGTON DISEASE DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 05: HUNTINGTON DISEASE DEAL ANALYTICS BY ANNUAL FREQUENCY
  • FIGURE 06: ACTIVE PLAYERS IN THE HUNTINGTON'S DISEASE MARKET
  • FIGURE 07: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 08: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 09: HD PIPELINE DRUGS ANTICIPATING US & EU MARKET APPROVALS, HSD SPLITUP
  • FIGURE 10: HUNTINGTON'S DISEASE DRUG PIPELINE SPLIT BY ROA
  • FIGURE 11: HSD WISE REPRESENTATION OF INJECTABLE DRUGS
  • FIGURE 12: HSD WISE REPRESENTATION OF ORAL DRUGS
  • FIGURE 13: UNMET NEEDS & CHALLENGES TO DRUG DELIVERY
  • FIGURE 14: VARIOUS DRUG CLASSES IN HD DRUG PIPELINE
  • FIGURE 15: HD DRUG PIPELINE SPLIT BY MOLECULE TYPE
  • FIGURE 16: HSD WISE SPLIT UP OF SMALL MOLECULE DRUGS
  • FIGURE 17: HSD WISE SPLIT UP OF BIOLOGIC DRUGS
  • FIGURE 18: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY TREATMENT TYPE
  • FIGURE 19: HUNTINGTON'S DISEASE PIPELINE DRUGS ANALYTICS BY TREATMENT TYPE AND HSD
  • FIGURE 20: HUNTINGTON'S DISEASES COMPANIES SPLIT BY COMPANY TYPE